Shares of US therapeutic gene editing company Sangamo Therapeutics (Nasdaq: SGMO) leapt 41% to $6.15 in after-hours trading on Wednesday, following the announcement of a deal worth a potential $545 million to the company.
Sangamo has entered into an exclusive, global collaboration and license agreement with US pharma giant Pfizer (NYSE: PFE) for the development and commercialization of gene therapy programs for hemophilia A, including SB-525, one of Sangamo's four lead product candidates, which Sangamo expects will enter the clinic this quarter.
Upfront payment of $70million
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze